Key Highlights

  • The first patient has been dosed in the phase 1 SAPPHIRE trial of ALA-101.
  • ALA-101 is an allogeneic, off-the-shelf CD19 CAR-iNKT cell therapy for blood cancers.
  • The trial is open-label, multi-centre and covers dose escalation and expansion.
  • Initial data from the trial are expected early in calendar year 2027.

Arovella Therapeutics Limited (ASX:ALA) announced on 27 October 2026 that it has dosed the first patient in its first-in-human phase 1 clinical trial of ALA-101, an allogeneic off-the-shelf cell therapy for blood cancers.

The SAPPHIRE Trial Design

The SAPPHIRE study, registered as ALA-101-001, is an open-label, multi-centre, dose-escalation and expansion trial. It will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of a single dose of ALA-101 in patients with relapsed or refractory CD19-positive non-Hodgkin lymphoma and leukaemia.

The first patient received ALA-101 after standard lymphodepleting chemotherapy at The Alfred in Melbourne under the supervision of lead investigator Dr Salvatore Fiorenza. During dose escalation, dosing will be staggered in line with regulatory requirements under the IND approval to allow safety review between patients.

About ALA-101

ALA-101 is an allogeneic CD19 CAR-iNKT cell therapy made from healthy donor cells, which the company says can be manufactured in advance and delivered when needed. Conventional CAR-T therapies use a patient’s own cells, and the company described that process as costly and time-consuming. The technology is licensed from Imperial College London.

Arovella’s Acting Chief Executive described the dosing as the culmination of several years of scientific, manufacturing, regulatory and clinical development. The company said the trial will provide information on the safety, expansion, persistence and B cell-depleting activity of the therapy, and will support development of its wider CAR-iNKT platform across blood cancers, solid tumours and autoimmune diseases. Initial data are expected early in calendar year 2027.

Why This Could Matter

Dosing the first patient moves ALA-101 from preparation into clinical testing in humans, the first time the therapy is delivered to a patient. The trial is at the safety and dose-finding stage, so the early results will address tolerability and biological activity and not yet the therapy’s effectiveness in a wider group of patients.

Wrapping Up

Arovella has begun clinical testing of ALA-101 with a first patient dosed in a phase 1 study. The company has not reported any patient results, and the first data are expected in early 2027.